BioMarin Pharmaceutical Inc.

BIT:1BMRN Stock Report

Market Cap: €10.0b

BioMarin Pharmaceutical Valuation

Is 1BMRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1BMRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1BMRN (€52.14) is trading below our estimate of future cash flow value (€189.13)

Significantly Below Future Cash Flow Value: 1BMRN is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1BMRN?

Key metric: As 1BMRN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1BMRN. This is calculated by dividing 1BMRN's market cap by their current earnings.
What is 1BMRN's PE Ratio?
PE Ratio42.4x
EarningsUS$268.74m
Market CapUS$11.40b

Price to Earnings Ratio vs Peers

How does 1BMRN's PE Ratio compare to its peers?

The above table shows the PE ratio for 1BMRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average13.1x
PHIL Philogen
4.1x-107.28%€936.5m
REC Recordati Industria Chimica e Farmaceutica
22.2x15.27%€10.5b
ARBS Arterra Bioscience
9.5xn/a€19.0m
EXEL Exelixis
16.5x10.42%US$13.8b
1BMRN BioMarin Pharmaceutical
42.4x24.71%€11.4b

Price-To-Earnings vs Peers: 1BMRN is expensive based on its Price-To-Earnings Ratio (42.4x) compared to the peer average (13.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 1BMRN's PE Ratio compare vs other companies in the European Biotechs Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1BMRN 42.4xIndustry Avg. 15.7xNo. of Companies8PE020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1BMRN is expensive based on its Price-To-Earnings Ratio (42.4x) compared to the European Biotechs industry average (15.7x).

Price to Earnings Ratio vs Fair Ratio

What is 1BMRN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1BMRN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.4x
Fair PE Ratio42.1x

Price-To-Earnings vs Fair Ratio: 1BMRN is expensive based on its Price-To-Earnings Ratio (42.4x) compared to the estimated Fair Price-To-Earnings Ratio (42.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1BMRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€52.14
€77.19
+48.04%
21.41%€105.44€43.94n/a26
Jun ’27€48.00
€75.30
+56.88%
21.41%€102.86€42.86n/a26
May ’27€46.55
€76.94
+65.28%
19.30%€102.40€46.93n/a24
Apr ’27€48.88
€77.49
+58.52%
18.68%€104.63€47.95n/a23
Mar ’27€53.02
€74.59
+40.68%
18.49%€101.51€46.52n/a23
Feb ’27€46.76
€75.26
+60.95%
20.50%€101.19€49.76n/a23
Jan ’27€50.42
€76.12
+50.97%
20.96%€103.48€50.89n/a23
Dec ’26€47.60
€77.08
+61.94%
19.65%€105.24€47.44n/a25
Nov ’26€45.53
€78.60
+72.62%
19.62%€105.84€47.71n/a25
Oct ’26€47.28
€82.23
+73.92%
16.40%€104.63€51.46n/a26
Sep ’26€49.31
€83.85
+70.05%
15.23%€104.80€55.84n/a26
Aug ’26€49.63
€83.13
+67.50%
14.90%€105.36€56.13n/a27
Jul ’26€47.50
€81.26
+71.07%
14.73%€103.48€55.13n/a28
Jun ’26€51.06
€84.62
+65.73%
14.62%€107.64€57.35€48.0028
May ’26€55.84
€85.80
+53.65%
15.49%€111.60€57.57€46.5528
Apr ’26€64.74
€89.39
+38.08%
15.32%€116.40€60.05€48.8828
Mar ’26€66.96
€93.01
+38.91%
15.38%€121.12€62.48€53.0228
Feb ’26€61.64
€94.15
+52.74%
16.08%€123.96€63.45€46.7627
Jan ’26€63.38
€93.89
+48.14%
16.55%€122.54€62.72€50.4226
Dec ’25€62.30
€92.71
+48.81%
16.71%€121.01€61.93€47.6028
Nov ’25€61.04
€89.54
+46.69%
16.84%€116.94€59.85€45.5327
Oct ’25€63.32
€94.23
+48.82%
16.45%€125.06€64.78€47.2825
Sep ’25€81.50
€99.39
+21.95%
14.20%€125.83€64.71€49.3125
Aug ’25€79.04
€100.94
+27.70%
15.16%€129.15€66.42€49.6325
Jul ’25€77.24
€101.18
+31.00%
15.91%€130.82€67.28€47.5026
Jun ’25€68.54
€101.03
+47.40%
14.29%€129.37€73.93€51.0626
€77.63
Fair Value
32.8% undervalued intrinsic discount
26
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 07:08
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioMarin Pharmaceutical Inc. is covered by 47 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Ying HuangBarclays
Eliana MerleBarclays